In vitro activity of St. John's wort against cytochrome P450 isozymes and P-glycoprotein

Pharmaceutical Biology

Volumn 42, Issue 2, 2004, Pages 159-169

  Foster, Bryan C ^a   Sockovie, E R ^b   Vandenhoek, S ^b   Bellefeuille, N ^b   Drouin, C E ^b   Krantis, A ^b   Budzinski, J W ^b   Livesey, J ^b   Arnason, J T ^b  

^a HEALTH CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

3A4; Cytochrome P450; Drug interactions; Hyperforin; Hypericin; Inhibition; Metabolism; Natural health products; P glycoprotein; St. John's wort

Indexed keywords

BENZYLOXYRESORUFIN; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; GLYCOPROTEIN P; HEXANE; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; PSEUDOHYPERICIN; RESORUFIN DERIVATIVE; UNCLASSIFIED DRUG; WATER;

ARTICLE; DRUG ACTIVITY; DRUG CAPSULE; DRUG DISPOSITION; DRUG EFFECT; DRUG SOLUBILITY; ENZYME INHIBITION; HYPERICUM PERFORATUM; IN VITRO STUDY; LIPOPHILICITY; LIQUID LIQUID EXTRACTION; TABLET; TINCTURE;

CLUSIACEAE; HYPERICUM; HYPERICUM PERFORATUM;

EID: 9644310473     PISSN: 13880209     EISSN: None     Source Type: Journal    
DOI: 10.1080/13880200490512034     Document Type: Article

References (31)

1. Beckman SE, Sommi RW, Switzer J (2000): Consumer use of St. John's wort: A survey on effectiveness, safety, and tolerability. Pharmacotherapy 20: 568-574.
2. Breidenbach TH, Hoffmann MW, Becker TH, Schutt H, Klempnauer J (2000): Drug interaction of St. John's wort with cyclosporin. Lancet 355: 1912.
3. Budzinski J, Foster BC, Vandenhoek S, Arnason J (2000): An in vitro evaluation of human cytochrome P450 3 A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7: 273-282.
4. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W (2000): Lack of effect of St. John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 68: 605-612.
5. Büter B, Orlacchio C, Soldati A, Berger K (1998): Significance of genetic and environmental aspects in the field cultivation of Hypericum perforatum. Planta Med 64: 431-437.
6. Cheng TO (2000): St. John's wort interaction with digoxin. Arch Internal Med 160: 2548.
7. De Maat MM, Hoetelmans RM, Math RA, Van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH (2001): Drug interaction between St. John's wort and nevirapine. AIDS 15:420-421.
8. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000): St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68: 598-604.
9. Ernst E (2000): Adverse effects of herbal drugs in dermatology. Br J Dermatol 143: 923-929.
10. Foster BC, Foster MS, Vandenhoek S, Budzinski JW, Gallicano KD, Choudri S, Krantis A, Arnason JT (2001): An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmac Sci 4(2): 176-184.
11. GENTEST (1998): Human P-Glycoprotein (Pgp or MDRl) Membranes: GENTEST Technical Bulletin, GENTEST Corporation.
12. Gold JL, Laxer DA, Dergal JM, Lanctot KL, Rochon PA (2001): Herbal-drag therapy interactions: A focus on dementia. Curr Opin Clin Nutr Metab Care 4: 29-34.
13. Greeson JM, Sanford B, Monti DA (2001): St. John's wort (Hypericum perforatum): A review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 153: 402-414.
14. Hahn G (1992): Hypericum perforatum (St. John's wort) - A medicinal herb used in antiquity and still of interest today. J Naturopathic Med 3: 94-96.
15. Ingram KD, Dragosavac GB, Benner KG, Flora KD (2000): Risks of drug interactions with St. John's wort. AJG 95: 3323-3324.
16. Jellin JM (Ed.) (2000): St. John's wort. Natural Medicines Comprehensive Database, http://www.naturaldatabase.com/
17. Kurth H, Spreemann R (1998): Phytochemical characterization of various St. John's wort extracts. Adv Ther 15: 117-128.
18. Laakman G, Dienel A, Hueser M (1998): Clinical significance of hyperforin for efficacy of Hypericum extracts on depressive disorders of different severities. Phytomedicine 5: 435-442.
19. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC (2000): Effect of St. John's wort (Hypericum perforation) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 66: 133-139.
20. Miller LG (1998): Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158: 2200-2211.
21. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000): St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97: 7500-7502.
22. Nebel A, Schneider BJ, Baker RK, Kroll DJ (1999): Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 33: 502.
23. Ness J, Sherman FT, Pan CX (1999): Alternative medicine: What the data say about common herbal therapies. Geriatrics 54: 33-8, 40,43.
24. Obach RS (2000): Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294: 88-95.
25. Parker V, Wong AH, Boon HS, Seeman MV (2001): Adverse reactions to St. John's wort. Can J Psychiatry 46: 77-79.
26. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000): Indinavir concentrations and St. John's Wort. Lancet 355: 547-548.
27. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000): St. John's wort: Effect on CYP 3A4 activity. Clin Pharmacol Ther 67: 451-457.
28. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G (2000): Acute heart transplant rejection due to St. John's wort. Lancet 355: 548-549.
29. South well IA, Bourke CA (2001): Seasonal variation in hypericin content of Hypericum perforatum L. (St. John's wort). Phytochemistry 56: 437-441.
30. Southwell IA, Campbell MH (1991): Hypericin content variation in Hypericum perforatum in Australia. Phytochemistry 30: 475-478.
31. Wagner H, Bladt S (1994): Pharmaceutical quality of Hypericum extracts. Psychiatry Neurol. Suppl 1: S65-68.